메뉴 건너뛰기




Volumn 31, Issue 12, 2007, Pages 1755-1758

Systemic mastocytosis in association with chronic lymphocytic leukemia: A rare diagnosis

Author keywords

Alemtuzumab; Imatinib; Lymphoproliferative diseases; Myeloproliferative disease

Indexed keywords

ALEMTUZUMAB; CYCLOPHOSPHAMIDE; FLUDARABINE; IMATINIB; RITUXIMAB;

EID: 35648961030     PISSN: 01452126     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.leukres.2007.04.002     Document Type: Article
Times cited : (12)

References (20)
  • 2
    • 0034983045 scopus 로고    scopus 로고
    • Diagnostic criteria and classification of mastocytosis: a consensus proposal
    • Valent P., Horny H.P., Escribano L., et al. Diagnostic criteria and classification of mastocytosis: a consensus proposal. Leuk Res 25 (2001) 603-625
    • (2001) Leuk Res , vol.25 , pp. 603-625
    • Valent, P.1    Horny, H.P.2    Escribano, L.3
  • 3
    • 0034994550 scopus 로고    scopus 로고
    • Clinical and histopathological aspects of cutaneous mastocytosis
    • Wolff K., Komar M., and Petzelbauer P. Clinical and histopathological aspects of cutaneous mastocytosis. Leuk Res 25 (2001) 519-528
    • (2001) Leuk Res , vol.25 , pp. 519-528
    • Wolff, K.1    Komar, M.2    Petzelbauer, P.3
  • 4
    • 2642581620 scopus 로고    scopus 로고
    • Systemic mastocytosis with associated clonal haematological non-mast cell lineage diseases: a histopathological challenge
    • Horny H.P., Sotlar K., Sperr W.R., and Valent P. Systemic mastocytosis with associated clonal haematological non-mast cell lineage diseases: a histopathological challenge. J Clin Pathol 57 (2004) 604-608
    • (2004) J Clin Pathol , vol.57 , pp. 604-608
    • Horny, H.P.1    Sotlar, K.2    Sperr, W.R.3    Valent, P.4
  • 5
    • 33745918388 scopus 로고    scopus 로고
    • Mast cells in Waldenstrom's macroglobulinemia support lymphoplasmacytic cell growth through CD154/CD40 signaling
    • Tournilhac O., Santos D.D., Xu L., et al. Mast cells in Waldenstrom's macroglobulinemia support lymphoplasmacytic cell growth through CD154/CD40 signaling. Ann Oncol 17 (2006) 1275-1282
    • (2006) Ann Oncol , vol.17 , pp. 1275-1282
    • Tournilhac, O.1    Santos, D.D.2    Xu, L.3
  • 6
    • 33745899005 scopus 로고    scopus 로고
    • CD52 is expressed on human mast cells and is a potential therapeutic target in Waldenstrom's Macroglobulinemia and mast cell disorders
    • Santos D.D., Hatjiharissi E., Tournilhac O., et al. CD52 is expressed on human mast cells and is a potential therapeutic target in Waldenstrom's Macroglobulinemia and mast cell disorders. Clin Lymphoma Myeloma 6 (2006) 478-483
    • (2006) Clin Lymphoma Myeloma , vol.6 , pp. 478-483
    • Santos, D.D.1    Hatjiharissi, E.2    Tournilhac, O.3
  • 7
    • 0034649716 scopus 로고    scopus 로고
    • When and how to treat chronic lymphocytic leukemia
    • Dighiero G., and Binet J.L. When and how to treat chronic lymphocytic leukemia. N Engl J Med 343 (2000) 1799-1801
    • (2000) N Engl J Med , vol.343 , pp. 1799-1801
    • Dighiero, G.1    Binet, J.L.2
  • 8
    • 33644746629 scopus 로고    scopus 로고
    • An unusual case of systemic mastocytosis associated with chronic lymphocytic leukaemia (SM-CLL)
    • Horny H.P., Sotlar K., Stellmacher F., Valent P., and Grabbe J. An unusual case of systemic mastocytosis associated with chronic lymphocytic leukaemia (SM-CLL). J Clin Pathol 59 (2006) 264-268
    • (2006) J Clin Pathol , vol.59 , pp. 264-268
    • Horny, H.P.1    Sotlar, K.2    Stellmacher, F.3    Valent, P.4    Grabbe, J.5
  • 9
    • 0034759524 scopus 로고    scopus 로고
    • Systemic mast cell disease associated with B-chronic lymphocytic leukemia
    • Sanz M.A., Valcarcel D., Sureda A., et al. Systemic mast cell disease associated with B-chronic lymphocytic leukemia. Haematologica 86 (2001) 1106-1107
    • (2001) Haematologica , vol.86 , pp. 1106-1107
    • Sanz, M.A.1    Valcarcel, D.2    Sureda, A.3
  • 11
    • 0034727833 scopus 로고    scopus 로고
    • Genomic aberrations and survival in chronic lymphocytic leukemia
    • Dohner H., Stilgenbauer S., Benner A., et al. Genomic aberrations and survival in chronic lymphocytic leukemia. N Engl J Med 343 (2000) 1910-1916
    • (2000) N Engl J Med , vol.343 , pp. 1910-1916
    • Dohner, H.1    Stilgenbauer, S.2    Benner, A.3
  • 12
    • 4143105617 scopus 로고    scopus 로고
    • ZAP-70 compared with immunoglobulin heavy-chain gene mutation status as a predictor of disease progression in chronic lymphocytic leukemia
    • Rassenti L.Z., Huynh L., Toy T.L., et al. ZAP-70 compared with immunoglobulin heavy-chain gene mutation status as a predictor of disease progression in chronic lymphocytic leukemia. N Engl J Med 351 (2004) 893-901
    • (2004) N Engl J Med , vol.351 , pp. 893-901
    • Rassenti, L.Z.1    Huynh, L.2    Toy, T.L.3
  • 13
    • 35748931679 scopus 로고    scopus 로고
    • Wierda WG, O'Brien S, Ferrajoli A, et al. Salvage therapy with combined cyclophosphamide (c), fludarabine (f), alemtuzumab (a), and rituximab (r) (cfar) for heavily pre-treated patients with CLL. ASH Annual Meeting Abstracts 2005;106:719.
  • 15
    • 0346880065 scopus 로고    scopus 로고
    • Clinical, genetic, and therapeutic insights into systemic mast cell disease
    • Tefferi A., and Pardanani A. Clinical, genetic, and therapeutic insights into systemic mast cell disease. Curr Opin Hematol 11 (2004) 58-64
    • (2004) Curr Opin Hematol , vol.11 , pp. 58-64
    • Tefferi, A.1    Pardanani, A.2
  • 16
    • 0036204619 scopus 로고    scopus 로고
    • Surrogate markers of disease in mastocytosis
    • Akin C., and Metcalfe D.D. Surrogate markers of disease in mastocytosis. Int Arch Allergy Immunol 127 (2002) 133-136
    • (2002) Int Arch Allergy Immunol , vol.127 , pp. 133-136
    • Akin, C.1    Metcalfe, D.D.2
  • 17
    • 33344458341 scopus 로고    scopus 로고
    • Elevated tryptase levels are associated with greater bone density in a cohort of patients with mastocytosis
    • Kushnir-Sukhov N.M., Brittain E., Reynolds J.C., Akin C., and Metcalfe D.D. Elevated tryptase levels are associated with greater bone density in a cohort of patients with mastocytosis. Int Arch Allergy Immunol 139 (2006) 265-270
    • (2006) Int Arch Allergy Immunol , vol.139 , pp. 265-270
    • Kushnir-Sukhov, N.M.1    Brittain, E.2    Reynolds, J.C.3    Akin, C.4    Metcalfe, D.D.5
  • 18
    • 0034987848 scopus 로고    scopus 로고
    • Clinical utility of tryptase levels in systemic mastocytosis and associated hematologic disorders
    • Schwartz L.B. Clinical utility of tryptase levels in systemic mastocytosis and associated hematologic disorders. Leuk Res 25 (2001) 553-562
    • (2001) Leuk Res , vol.25 , pp. 553-562
    • Schwartz, L.B.1
  • 19
    • 0028258512 scopus 로고
    • Activating mutations of the c-kit proto-oncogene in a human mast cell leukemia cell line
    • Kanakura Y., Furitsu T., Tsujimura T., et al. Activating mutations of the c-kit proto-oncogene in a human mast cell leukemia cell line. Leukemia 8 Suppl. 1 (1994) S18-S22
    • (1994) Leukemia , vol.8 , Issue.SUPPL. 1
    • Kanakura, Y.1    Furitsu, T.2    Tsujimura, T.3
  • 20
    • 27244451794 scopus 로고    scopus 로고
    • Fludarabine in combination with alemtuzumab is effective and feasible in patients with relapsed or refractory B-cell chronic lymphocytic leukemia: results of a phase II trial
    • Elter T., Borshmann P., Schulz H., et al. Fludarabine in combination with alemtuzumab is effective and feasible in patients with relapsed or refractory B-cell chronic lymphocytic leukemia: results of a phase II trial. J Clin Oncol 23 (2005) 7024-7031
    • (2005) J Clin Oncol , vol.23 , pp. 7024-7031
    • Elter, T.1    Borshmann, P.2    Schulz, H.3


* 이 정보는 Elsevier사의 SCOPUS DB에서 KISTI가 분석하여 추출한 것입니다.